Hodgkin's Lymphoma

Oncology·MeSH: Hodgkin Disease

Prevalence

56.0 / 100K

Incidence

19.6 / 100K/yr

28 drugs in development·10 companies·1 clinical trial

Drug Pipeline by Phase

Approved(3)

Drug	Company
carmustine	Amneal Pharmaceuticals, Inc. (AMRX)
Tyvyt	ELI LILLY & Co (LLY)
Tyvyt®	ELI LILLY & Co (LLY)

Phase 3(11)

Phase 2(3)

Drug	Company
ABT-199	AbbVie Inc. (ABBV)
cd19t-hank	ImmunityBio, Inc. (IBRX)
n803 plus bacillus calmette-guerin	ImmunityBio, Inc. (IBRX)

Phase 1(9)

Drug	Company
[14C]ABT-199	AbbVie Inc. (ABBV)
100 µci [14c] hmpl-306	HUTCHMED (China) Limited (HCM)
bendamustine	AbbVie Inc. (ABBV)
Fludarabine	ImmunityBio, Inc. (IBRX)
hmpl-760	HUTCHMED (China) Limited (HCM)
Ketoconazole	AbbVie Inc. (ABBV)
prt2527	Prelude Therapeutics Inc (PRLD)
Rifampin	AbbVie Inc. (ABBV)
sc262	Sana Biotechnology, Inc. (SANA)

Phase 1/Phase 2(2)

Drug	Company
eb103	Estrella Immunopharma Inc. (ESLA)
eb103	ESTRELLA IMMUNOPHARMA, INC. (UPTD)

BioSniper tracks 28 drugs in development for Hodgkin's Lymphoma across 10 companies.

There are 1 clinical trial targeting Hodgkin's Lymphoma tracked by BioSniper.

The estimated prevalence of Hodgkin's Lymphoma is approximately 56.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.